You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 197 Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
197 Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address